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ABSTRACT 
Objective To evaluate the efficacy and safety of oral levosimendan in amyotrophic 
lateral sclerosis (ALS) patients. This phase 2, randomised, double-blind, placebo-
controlled, crossover, 3-period study with 6 months open-label follow-up enrolled 
adults with ALS and sitting slow vital capacity (SVC) 60-90% of predicted from 11 
sites in four countries.  
Methods Patients received levosimendan 1 mg daily, 1 mg bd or placebo during 
three 14-day crossover periods, and levosimendan 1-2 mg daily during open-label 
follow-up. Primary endpoint was sitting SVC; secondary endpoints included supine 
SVC, ALS Functional Rating Scale (ALSFRS-R), tolerability and safety. 
Results Of 66 patients randomised, 59 contributed to the double-blind results and 
50 entered open-label follow-up. Sitting SVC was not significantly different 
between the treatments. In post hoc analysis using period-wise baselines, supine 
SVC favoured levosimendan over placebo, estimated mean differences from 
baseline being -3.62% on placebo, +0.77% on levosimendan 1 mg daily (p=0.018) 
and +2.38% on 1 mg bd (p=0.001). Headache occurred in 16.7% of patients during 
levosimendan 1 mg daily (p=0.030), 28.6% during 1 mg bd (p=0.002) and 3.3% 
during placebo. The respective frequencies for increased heart rate were 5.1% 
(p=0.337), 18.5% (p=0.018) and 1.7%.  No significant differences between the 
treatments were seen for other adverse events.  
Conclusions Levosimendan did not achieve the primary endpoint of improving 
sitting SVC in ALS. Headache and increased heart rate were increased on 
levosimendan, although it was otherwise well tolerated. A phase 3 study to evaluate 
the longer-term effects of oral levosimendan in ALS is ongoing. 
Keywords levosimendan, SVC, respiratory function, amyotrophic lateral sclerosis 
 
INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease of upper and 
lower motor neurons resulting in progressive weakness, with death occurring from respiratory 
failure commonly as a result of diaphragmatic weakness typically within three to four years. 
None of the current therapies offer substantial clinical benefit for patients with ALS, riluzole 
having a modest effect on survival and edaravone on the rate of functional decline.[1] Despite 
the beneficial effects of non-invasive ventilation, [2, 3] poor respiratory function is a major 
source of disability, fatigue, morbidity and mortality in ALS, and there is an urgent need for an 
effective therapy to improve symptoms associated with the respiratory decline.  
 
Levosimendan binds selectively to troponin C sensitising cardiac and skeletal muscles to 
calcium,[4] and currently, an intravenous formulation of levosimendan is indicated for the 
treatment of acute worsening of severe heart failure. The mean elimination half-lives of 
levosimendan and its two active metabolites, OR-1855 and OR-1896, are about 1 and 60 h, 
respectively. Due to its having similar free plasma concentrations to levosimendan, OR-1896 is 
believed to contribute to therapeutic efficacy during prolonged treatment (Orion Pharma, data on 
file). Levosimendan does not increase consumption of adenosine triphosphate or oxygen [5] and 
does not cross the blood-brain-barrier.[6] 
 
There is a compelling scientific rationale for the development of an oral formulation of 
levosimendan for symptomatic treatment of ALS. Two experimental studies have shown that in 
diaphragm muscle fibres obtained from rats and humans, levosimendan improves submaximal 
force generation of diaphragm (both slow and fast muscle fibres) by about 15-25%.[7, 8] In 
addition, levosimendan has been reported to improve neuromechanical efficiency of human 
diaphragm function by 21% in healthy people.[9] Further support is provided by the 
development programs of other calcium sensitizers, tirasemtiv and reldesemtiv. In a phase 2b 
study, tirasemtiv showed a positive effect on sitting SVC, but not on the primary efficacy 
endpoint ALSFRS-R.[10] . 
 
We therefore carried out a phase 2 multicentre, randomised, double-blind, placebo-controlled 
trial of oral levosimendan in ALS. 
 
METHODS 
Study design and participants 
This was a randomised, double-blind, placebo-controlled, crossover, 3-period study with 6 
months open-label follow-up. Each treatment period lasted for 2 weeks separated by 19-23 day 
wash-out periods (online supplementary figure 1). There were 11 sites from the UK, Germany, 
Ireland and the Netherlands. The main inclusion criteria were: diagnosis of definite, probable or 
laboratory-supported probable ALS according to El Escorial revised criteria;[11] sitting slow 
vital capacity (SVC) 60-90% of predicted for age, height and gender, and disease duration from 
symptom onset of 12-48 months. The main exclusion criteria were: other causes of 
neuromuscular weakness; diagnosis of another neurodegenerative disease; assisted ventilation or 
gastrostomy within 3 months, and history of significant cardiac disease or cardiac events. All 
entry criteria are listed in online supplementary table 1. 
 
All participants provided written informed consent for the study. The study was conducted 
according to the Declaration of Helsinki and in compliance with Good Clinical Practice. An 
independent board monitored safety throughout the study. EudraCT number: 2014-004567-21; 
ClinicalTrials.gov identifier: NCT02487407. 
 
Study medications, randomisation and dosing 
Levosimendan 1 mg capsules and identical placebo capsules were used. Patients were 
randomised to three cross-over periods using 6 possible treatment sequences according to 
William’s design,[12] equal allocation ratio and central randomisation.  
 
Dosing was twice daily. During the 1 mg daily period, levosimendan 1 mg was taken in the 
morning and placebo in the evening. During the 2 mg daily period, dosing was 1 mg bd and 
during the placebo period, placebo capsules were taken bd. 
 
During open-label follow-up, all patients were started on 1 mg levosimendan taken in the 
morning for 2 weeks, after which the dose was increased to 1 mg bd if tolerated. The dose could 
be decreased back to 1 mg daily or discontinued if required for any reason. 
 
Efficacy assessments 
The primary endpoint was SVC (% of predicted normal) measured in the sitting position. 
Secondary endpoints included SVC measured supine, sniff nasal pressure (SNP), ALSFRS-R, 
overnight oxygen saturation (SpO2), hand grip strength, submaximal hand grip strength 
endurance, Clinical Global Impression of Change (CGI-C) assessed by patients and 
investigators, visual analogue scale (VAS) assessing fatigue, and quality of life (QoL) scales 
(EQ-5D-5L and SF-36). Non-invasive ventilation (NIV) support, permanent continuous 
ventilator dependence, tracheostomy and survival were recorded. During the 6 months open-
label follow-up period, sitting and supine SVC, SNP, ALSFRS-R, EQ-5D-5L and SF-36 were 
assessed (see online supplementary file and online (supplementary Table 2).  
 
Safety assessments 
Safety was assessed by physical examination, vital signs, laboratory tests, 12-lead 
electrocardiogram (ECG), 24-hour Holter ECG and recording of adverse events (AEs).  
 
Other assessments 
Plasma samples for levosimendan, OR-1855, OR-1896 and riluzole concentrations were 
collected in the morning before study treatment intake on days 1 and 14 of each treatment period. 
DNA samples were collected for pharmacogenomic assessments and acetylation status, based on 
polymorphism in the N-acetyltransferase enzyme affecting the metabolism of OR-1855 to OR-
1896. All study assessments are presented in online supplementary table 2. 
 
Statistical analyses 
Sample size estimation was based on additional results from the BENEFIT-ALS trial.[10] SVC 
was assumed to decline during each double-blind crossover period by 4% for placebo and 1% for 
levosimendan, with a common standard deviation (SD) of 9% and within subject correlation of 
0.70. A sample size of 54 provides over 80% power at 5% significance. 
 
Intention-to-treat analysis without imputation for missing data was used throughout reporting. 
Appropriate descriptive statistics, frequency tables and plots were used to summarise all data. 
 
The primary efficacy endpoint was change in sitting SVC, comparing baseline (period 1 day 1) 
and day 14 pre-dose assessments. Due to a significant period effect, changes from period-wise 
baselines (period 1 day 1, period 2 day 1 and period 3 day 1, respectively) were analysed as 
primary comparisons post hoc. Analysis of co-variance (ANCOVA), appropriate to crossover 
design, was used for primary analysis. The statistical model included treatment dose, baseline 
SVC, treatment sequence and period as fixed effects and subject and site as random effects. All 
pairwise comparisons were performed using Tukey adjustment. Slope of decline in SVC was 
evaluated including all data from both double-blind crossover and open-label follow-up using a 
random slope and intercept model. 
 
Secondary efficacy endpoints were primarily evaluated at the end of the double-blind crossover. 
A 2-sided 0.05 significance level was allocated for the analyses of secondary variables. The 
secondary efficacy variables were analysed using the same statistical principles as the primary 
variable. Respiratory function and quality of life endpoints were evaluated during the open-label 
follow-up using descriptive statistics only. 
 
Levosimendan, OR-1855, OR-1896 and riluzole concentrations were summarised and plotted 
using descriptive statistics. Acetylation status was determined from all subjects participating in 
the study. Acetylation status was summarized by treatments and the effects of acetylation status 
on levosimendan, metabolites, SVC, SNP and ambulatory heart rate (HR) were evaluated using 
analysis of variance (ANOVA) appropriate for the crossover design. Potential effects of 
levosimendan treatment on riluzole concentration were evaluated using ANOVA. 
 
Safety data including AEs, vital signs, laboratory results, 12-lead ECG and 24-hour Holter-ECG 
were displayed by treatment and study part (crossover and open-label). 
 
RESULTS 
Study population 
Of the 66 patients randomised, 71.2% were male, 92.4% white European, and 83.3% had spinal-
onset disease. Median disease duration from symptom onset was 21.2 months (table 1). 
Table 1 Baseline demographics and characteristics 
Variable 
Total 
N = 66 
Age, years 
Median 56.5 
Range 36-75 
Sex, n (%) 
Male 47 (71.2) 
Female 19 (28.8) 
Weight, kg Mean (SD) 76.7 (15.9) 
Variable 
Total 
N = 66 
BMI, kg/m2 Mean (SD) 25.6 (4.0) 
Race, n (%) 
Caucasian 61 (92.4) 
Asian 3 (4.5) 
Black 1 (1.5) 
Other 1 (1.5) 
Disease duration from symptom 
onset, months 
Median 21.2 
Range 12-48 
Sitting SVC % of predicted Mean (SD) 75.3 (9.1) 
Supine SVC % of predicted Mean (SD) 73.3 (14.0) 
ALSFRS-R Mean (SD) 36.7 (5.4) 
Site of disease onset, n (%) 
Spinal 55 (83.3) 
Bulbar 11 (16.7) 
Treated with riluzole, n (%)  66 (100) 
BMI: body mass index; SD: standard deviation; SVC: slow vital capacity; ALSFRS-R: amyotrophic lateral sclerosis 
functional rating scale-revised 
 
Study medication exposure 
During the crossover, double-blind part of the study, 59 patients received levosimendan 1 mg 
daily, 59 levosimendan 1 mg bd and 58 placebo.  
 
In the open-label follow-up part of the study, 50 people received levosimendan, 44 of them 
increasing the dose from 1 mg to 2 mg daily at 2 weeks (figure 1). The mean duration of the 
treatment for all study participants was 147.9 days (range 6-195 days) during the open-label 
follow-up. 
 
Efficacy in the crossover, double-blind part of the study 
We initially designed the study under the assumption that patients would not deteriorate 
significantly during the first 3 months, and therefore that the baseline of the first treatment period 
would be appropriate to use as baseline for all treatment periods. However, due to a significant 
period effect (p < 0.0001) with period-wise baseline affected by previous treatment period, the 
data did not allow appropriate interpretation of efficacy using the Period 1, Day 1 baseline for all 
periods. We therefore performed a post hoc period-wise analysis with the period-specific 
baseline used for each period (e.g. Period 2, Day 1 baseline for Period 2). 
 
Sitting SVC 
Using the original baseline definition, estimated mean differences from baseline in sitting SVC 
were -2.01% for placebo, -2.99% for levosimendan 1 mg daily (p = 0.67 vs. placebo), and -
2.25% for levosimendan 2 mg daily (p = 0.98 vs. placebo). Using period-wise baselines (post 
hoc), the differences between levosimendan and placebo remained similar (data not shown).  
 
Supine SVC 
There is no formula to predict the effects of age, height and gender on supine SVC, and expected 
values were therefore calculated using the formula for sitting SVC. Using the original baseline 
definition, mean differences from baseline were -4.51% for placebo, -2.57% for levosimendan 1 
mg daily (p = 0.35 vs. placebo) and -1.97 % points for levosimendan 2 mg daily (p = 0.17 vs. 
placebo). Using period-wise baselines (post hoc), mean differences from baseline were -3.62% 
for placebo, +0.77 for levosimendan 1 mg daily (p = 0.018 vs. placebo) and +2.38 % points for 
levosimendan 2 mg daily (p < 0.001 vs. placebo). Supine SVC results using the period-wise 
baselines (post hoc) are presented for each period separately and all the periods combined in 
figure 2, and the results with the primary analyses are shown for each period separately in online 
supplementary figure 2. 
 
Patients with bulbar onset had lower baseline supine SVC than patients with spinal onset. In the 
subgroup analyses, changes from baseline were different depending on onset site (p = 0.008 for 
interaction), the treatment effect being larger in patients with bulbar onset (-9.02 for placebo, 
+4.06 levosimendan 1 mg daily (p = 0.003 vs. placebo) and +5.06, levosimendan 2 mg daily (p = 
0.001 vs. placebo). Numerically greater treatment effects were seen in patients who had baseline 
supine SVC below the median value of 75.0% points (p = 0.291 for interaction): -7.00 for 
placebo, -0.02 levosimendan 1 mg daily (p = 0.049 vs. placebo) and +1.14, levosimendan 2 mg 
daily (p = 0.016 vs. placebo).  
 
ALSFRS-R 
There was no significant difference in the ALSFRS-R total or respiratory scores. Estimated mean 
differences from baseline were -0.82 for placebo, -0.46 for levosimendan 1 mg daily (p = 0.49 
vs. placebo) and -0.37 for levosimendan 2 mg daily (p = 0.34 vs. placebo). Estimated mean 
differences from baseline in respiratory domain scores were -0.22 for placebo, +0.04 for 
levosimendan 1 mg daily (p = 0.13 vs. placebo) and +0.05 for levosimendan 2 mg daily (p = 0.12 
vs. placebo).  
Other efficacy endpoints 
There were no trends seen between placebo and levosimendan in SNP, VAS of fatigue, overnight 
SpO2, hand grip assessments, CGI-C or in QoL scales. 
 
Key efficacy parameters during the 6 months open-label part of the study are presented in the 
online supplement. 
Tolerability and safety  
In the double-blind crossover part of the study, AEs were reported by 71% during levosimendan 
1 mg daily, 85% levosimendan 2 mg daily and 53% of patients on placebo. Most of the AEs 
were mild, with severe AEs reported in isolated cases only. The most commonly reported AEs 
during the crossover part were headache, fall, and increased HR (terms ‘heart rate increased’, 
‘tachycardia’ and ‘sinus tachycardia’ combined) (table 2). Of the 50 patients continuing to open-
label follow-up, AEs were reported for 42 (84%), with the most commonly reported events being 
fall (28%), dysphagia (12%), respiratory failure (12%), headache (10%) and nasopharyngitis 
(8%). 
 Table 2 Most common AEs during the study 
Preferred term 
Double-blind cross-over Open-label follow-up 
Levosimendan  
1 mg 
N = 59 
Levosimendan  
1 mg bd 
N = 59 
Placebo 
N = 58 
Levosimendan 
1-2 mg 
N = 50 
Participants (%) 
Headache 10 (16.9)‡ 17 (28.8)† 2 (3.4) 5 (10.0) 
Fall 9 (15.3) 9 (15.3) 5 (8.6) 14 (28.0) 
Heart rate increased* 3 (5.1)⸸ 11 (18.6)ǂ 1 (1.7) 1 (2.0) 
Nasopharyngitis 4 (6.8) 4 (6.8) 3 (5.2) 4 (8.0) 
Cough 6 (10.2) - 1 (1.7) 3 (6.0) 
Contusion 2 (3.4) 4 (5.1) 1 (1.7) - 
Nausea 4 (6.8) 1 (1.7) 1 (1.7) 3 (6.0) 
Diarrhoea 1 (1.7) 3 (5.1) 1 (1.7) 3 (6.0) 
Constipation 2 (3.4) 2 (3.4) 3 (5.2) 1 (2.0) 
Oxygen saturation decreased** 3 (5.1) 4 (6.8) - 1 (2.0) 
*Preferred terms ‘heart rate increased’, ‘tachycardia’ and ‘sinus tachycardia’ combined 
**Decreased oxygen saturation was reported in a total of 2 patients from 2 centers 
‡ p=0.030, † p=0.002, ⸸ p=0.337, ǂ p=0.018 
 
During the double-blind crossover part of the study, 13 of the 66 patients discontinued the study 
due to an AE, the most common reason being increase in HR fulfilling a predefined study 
treatment stopping rule (1 during levosimendan 1 mg daily, 8 during 2 mg daily and 1 during 
placebo). Based on the 24-hour Holter-ECG, mean changes from baseline in mean HR were 5.2 
bpm during levosimendan 1 mg daily, 10.7 bpm during 2 mg daily, and -0.4 bpm during placebo. 
Other AEs leading to discontinuation of the study during the crossover periods were headache 
(n = 1) and atrial fibrillation and electrocardiogram QT prolonged (n = 1) during levosimendan 2 
mg daily, and bradycardia and cardiac arrest (n = 1) during placebo. During the open-label 
follow-up, six subjects discontinued the study due to AEs, five of them being serious adverse 
events (SAEs) (pulmonary embolism, aspiration pneumonia, respiratory failure, acute 
myocardial infarction and dysphagia) and one non-serious AE (heart rate increased).  
 
During the crossover part of the study, SAEs were reported in four (7%) patients both during 
levosimendan 1 mg daily and placebo and in two (3%) patients during levosimendan 2 mg daily. 
19 patients (38%) reported SAEs during open-label follow-up. The most commonly reported 
SAE terms were respiratory failure, dysphagia and ALS. Two of the SAEs were assessed as 
related to the study treatment by the investigator: bradycardia and cardiac arrest during placebo 
in the crossover part and acute myocardial infarction during the open-label follow-up. Five 
patients died during the study (one during the crossover and 4 during the open-label part of the 
study); in all cases, the death was assessed as not related to the study treatment by the 
investigator. Two patients died of ALS and one each of ‘pneumonia aspiration, ‘pneumonia 
bacterial, myocardial infarction and pneumothorax’ and ‘respiratory failure’.  
 
Mean changes from baseline in supine systolic blood pressure were numerically greater after 
levosimendan (from -4.0 to -8.6 mmHg) than after placebo (from 1.9 to -0.1 mmHg). Changes in 
diastolic blood pressure were similar to those in systolic blood pressure. No differences were 
seen in mean orthostatic test results between treatments. 
 
Levosimendan, OR-1855, OR-1896 and riluzole concentrations  
Slow acetylators had higher OR-1855 concentrations, but lower OR-1896 concentrations than 
rapid acetylators (online supplementary table 3). Samples taken after the wash-out period did not 
indicate any carry-over effects. Acetylation status had no effect on supine SVC effect observed 
(interaction p=0.667), the apparent treatment effect being similar in slow (2 mg daily 2.05%, 1 
mg daily 1.79% and placebo -3.22%) and fast (2 mg daily 2.57%, 1 mg daily -0.55% and placebo 
-4.45%) acetylators. 
 
There were no differences in plasma concentrations of riluzole between day 1, day 14 or between 
the treatment periods (data not shown).  
 
DISCUSSION 
This was the first study with oral levosimendan in patients with ALS. The study was designed to 
find treatment differences within a short period of time with three crossover periods during 
double-blind comparison. 14-day treatment periods were selected based on earlier studies 
reporting that a single oral 1 mg dose of levosimendan was able to increase cardiac output in 
patients with severe heart failure by 22% (p < 0.005; Orion Pharma data on file) and that a short 
levosimendan infusion improved diaphragm function in healthy people.[9] It was expected, 
however, that most of the outcome measures such as ALSFRS-R [13]and quality of life scales 
would not show any differences within 14 day periods.  
 
In contrast to our primary assumptions, there was a clear period effect (but no carry-over effect) 
seen in the crossover part of the study, and therefore the efficacy results were analysed period-
wise, using period-specific baselines (post hoc analyses). Although the primary endpoint of 
sitting SVC did not show significant differences between the treatments, supine SVC in the post 
hoc analyses indicated a dose-related treatment effect favouring levosimendan against placebo 
(4.39% points difference between placebo and levosimendan 1 mg and 6.00% points difference 
between placebo and 2 mg). Similar results were seen during all three periods, effectively 
replicating the findings two further times, thus strengthening our confidence in the results (figure 
2). Diaphragmatic performance is reduced more dramatically by lying than by sitting, and the 
first clinical signs of respiratory insufficiency often appear during sleeping or when lying down. 
[14, 15] Seeing differences between the treatments in supine but not sitting SVC is supported by 
the finding that in patients with ALS, supine vital capacity is a more sensitive measure of 
diaphragmatic strength than that measured in the upright position, suggesting that upright vital 
capacity might not reveal abnormalities becoming noticeable in the supine position.[16] There is 
also evidence that supine vital capacity is a better predictor of survival than upright vital capacity 
[17, 18], and among several different respiratory measures, it has been reported to correlate most 
closely with diaphragmatic weakness, especially in patients with vital capacity < 75% of 
predicted.[16] Treatment effects seen in supine SVC between levosimendan and placebo 
treatments in patients with SVC < 75% predicted at baseline are in line with this expectation. 
Although no significant changes were seen, both the ALSFRS-R total score and respiratory 
domain subscore numerically favoured levosimendan, supporting the supine SVC results. 
However, one needs to be cautious in interpreting ALSFRS-R results as the absolute differences 
were small and the treatment duration was short. Apart from supine SVC, other secondary 
efficacy endpoints did not show any difference between treatments. 
 
All 50 patients completing the crossover part of the study continued to the open-label follow-up. 
Mean supine SVC at study baseline was 73.3% points and declined to 61.8% points at end of the 
6 months open-label follow-up. In turn, mean ALSFRS-R total score was 36.7 points at baseline 
and declined to 28.9 points at the end of open-label follow-up. During the entire 9 months study, 
the mean decline in supine SVC and ALSFRS-R total score were 1.93% points/month and 1.03 
points/month, respectively. Mean declines were smaller over the last 6 months when all patients 
were on levosimendan. Based on a previous retrospective analysis, slowing the rate of decline of 
SVC by 1.5% point monthly (from -4.23 to −2.73 and to −1.23) corresponds to a reduction of 
about 20% in the risk for respiratory events or death.[19] In light of this analysis, our results are 
encouraging, but no conclusions can be drawn since our uncontrolled data from the open-label 
follow-up are not directly comparable due to differences in study design and duration, and the 
position in which SVC was measured.  
 
In patients with rapid acetylator status more active metabolite OR-1896 of levosimendan is 
formed [20] and the active metabolite levels were higher in rapid than slow acetylators in this 
study. Despite this, there was no difference in the change of supine SVC. This is in line with 
earlier findings in heart failure patients, in whom hemodynamic effects were similar in rapid and 
slow acetylators.[20] 
 
Levosimendan was generally well tolerated. Headache and increase in HR were more common 
during levosimendan treatment than placebo showing a dose-dependent increase in frequency. 
Headache, most probably due to vasodilatation by levosimendan, was usually short-lasting and 
did not result in discontinuation of the study except for one patient with a medical history of 
migraine. In most cases, the increase in HR was reported as an AE based on a predefined study 
treatment stopping rule (increase in mean HR of over 15 bpm from baseline in the 24-hour 
Holter recording) and was not due to subjective symptoms of tachycardia. Most of the other 
frequently reported AEs, such as falls, nasopharyngitis, dysphagia and respiratory failure, were 
not considered to be related to the study treatment, reflecting the signs and symptoms of ALS. 
Supraventricular and ventricular tachyarrhythmias were reported in a low number of patients and 
were evenly distributed across the treatment arms. AEs such as dizziness or somnolence were 
reported as isolated events only and no AEs such as ataxia, agitation, confusion or delirium were 
reported in the study. All deaths and most other SAEs were assessed as not related to the study 
treatment by the investigator, indicating incidental events expected to be related to ALS. 
 
In summary, we found no evidence that levosimendan improves SVC in the sitting position. 
Levosimendan treatment was well tolerated but with a dose-dependent increase in headache and 
tachycardia compared to placebo. In the light of the post- hoc analysis indicating a possible dose-
dependent treatment effect of levosimendan on the supine SVC compared with placebo, a phase 
3 study is ongoing to evaluate longer-term effects of oral levosimendan in ALS (NCT03505021) 
(Supplementary video). 
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Figure 1 Disposition of subjects. AE: adverse event 
 
 
Figure 2. SVC (percent of predicted normal) measured in the supine position. Change from period-wise 
baselines (period 1 day 1, period 2 day 1 and period 3 day 1, respectively; post-hoc analysis) in percent 
predicted SVC is shown for all three 14-day cross-over treatmen 
 
Online supplement, efficacy in the open-label part of the study 
 
During the open label follow-up, the mean sitting SVC value declined from the baseline value of 
73.7% points (n = 66) to 70.5 points at 1 month (n = 43), 66.4 at 3 months (n = 40), and 63.3% at 
6 months (n = 30). The average decline in sitting SVC was 1.75 % points/month during the 9 
month study. 
 
The mean supine SVC declined from the baseline value of 73.3% points (n = 66) to 64.9 (n = 43) 
at 1 month, 63.6 (n = 35) at 3 months, and 61.8% points (n = 28) at 6 months. The average 
decline in supine SVC was 1.93 % points/month during the 9 month study.  
 
The mean ALSFRS-R total score declined from the baseline value of 36.7 points (n=66) to 32.6 
(n=46) at 1 month, 30.2 (n=43) at 3 months, and 28.9 (n = 36) at 6 months. The average decline 
in ALSFRS-R total score was 1.03 points/month during the 9 month study. 
 
The mean SNP value declined from the baseline value of 56.7 cmH2O (n = 66) to 52.2 (n = 46) 
at 1 months, 53.4 (n = 41) at 3 months, and 51.1 (n = 34) at 6 months. The average decline in 
SNP was 1.76 cmH2O /month during the 9 month study.During the open label follow-up, the 
mean overnight SpO2 did not change from the baseline value. Worsening EQ-5D-5L and SF-36 
results were seen throughout the study period (data not shown). 
 
 
  
Online supplementary table 1. Entry criteria 
Inclusion criteria 
1.  Written or verbal IC for participation in the study was obtained from the subject. In case the study 
subject him/herself could not sign the IC due to severe muscle weakness, a witness could sign the 
consent form to indicate that the subject had given verbal consent. 
2.  Age of at least 18 years. 
3.  Male or female subjects with diagnosis of laboratory supported probable, probable or definite ALS 
according to El Escorial revised criteria (Brooks BR et al., 2000). Full electromyogram (EMG) report 
available consistent with ALS (but not necessarily fulfilling electrodiagnostic criteria for ALS) from 
an experienced neurophysiologist 
4.  Ability to swallow the study treatment capsules. 
5.  An upright (sitting position) SVC between 60-90% of the predicted value for age, height and sex at 
screening visit. 
6.  Normal oxygen saturation during daytime (measure of ≥ 95% when steady state has been reached 
with a reliable read) in sitting position measured by pulse oximetry. 
7.  Disease duration from symptom onset (defined by first muscle weakness or dysarthria) of 12-48 
months at the time of baseline/day 1 of the first treatment period. 
8.  Patients with or without riluzole. If using riluzole, the dose must have been stable for at least 4 weeks 
prior to screening and should not be changed during the crossover, double-blind part of the study. 
Exclusion criteria 
1.  Subject in whom other causes of neuromuscular weakness had not been excluded. 
2.  Subject with a diagnosis of another neurodegenerative disease (e.g. Parkinson’s or Alzheimer’s 
disease). 
3.  Assisted ventilation or gastrostomy of any type during the preceding 3 months prior to screening or 
predicted to be required within the randomised, double-blind crossover part of the study. 
4.  Recorded diagnosis or evidence of major psychiatric diagnosis, significant cognitive impairment or 
clinically evident dementia. 
5.  Haemodynamically significant uncorrected valve disease or hypertrophic cardiomyopathy or 
restrictive cardiomyopathy. 
6.  Acute myocardial infarction or any other acute coronary event within 1 month before the screening 
visit. 
7.  Any major surgery within 1 month before the screening visit or patients who were scheduled for any 
major surgery during the planned study period. 
8.  History of Torsades de Pointes (TdP), family history of long QT-syndrome or history of life-
threatening ventricular arrhythmia within 3 months before screening. 
9.  HR < 50 or > 100 bpm as an average over the 24-hour ambulatory Holter-ECG recording at 
screening. 
10.  Systolic blood pressure (SBP) < 100 mmHg or > 180 mmHg, or diastolic blood pressure (DBP) > 100 
mmHg at screening. 
11.  Ventricular tachycardia (wide complex tachycardia > 100/min, > 5 consecutive beats) in the 24-hour 
ambulatory Holter-ECG recording at screening. 
12.  Episode of atrial fibrillation or atrial flutter lasting > 60 seconds in 24-hour ambulatory Holter-ECG 
recording at screening. 
13.  Second or third degree atrioventricular (AV) block in the 12-lead ECG or in the 24-hour ambulatory 
Holter-ECG recording at screening. 
14.  Potassium < 3.7 mmol/l or > 5.5 mmol/l at screening. 
15.  Creatinine > 170 µmol/l at screening or on dialysis. 
16.  Blood haemoglobin < 10 g/dl at screening. 
17.  Clinically significant hepatic impairment at the discretion of the investigator. 
18.  Women of reproductive age without a negative pregnancy test and without a commitment to using an 
acceptable method of barrier or hormonal contraception (e.g. condoms, diaphragms, oral 
contraceptives and long acting progestin agents), if sexually active during the study, and for 1 month 
after the last dose of the study treatment. 
19.  Known hypersensitivity to levosimendan. 
20.  Administration of levosimendan within 30 days prior to screening visit. 
21.  Any botulinum toxin use within 3 months from screening. Use of botulinum toxin was not allowed 
during double-blind, crossover part of the study 
22.  Patients with known history of human immunodeficiency virus (HIV) infection. 
23.  Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, 
neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the 
investigator could have interfered with the interpretation of the study results or constituted a health 
risk for the subject if he/she took part in the study. 
24.  Blood donation or loss of significant amount of blood within 60 days prior to screening. 
25.  Participation in a clinical trial with any experimental treatment within 30 days prior to the screening 
visit or previous participation in the present study. 
26.  Any other condition that in the opinion of the investigator could have interfered with the 
interpretation of the study results or constituted a health risk for the subject if he/she took part in the 
study. 
Online supplementary table 2. Study event table 
Protocol activities 
Screening 
period 
Double-blind crossover part 
Visits/each treatment period 
Open-label 
Follow-up extension 
Post-
treatment 
period 
Screening 
visit 
Baseline 
Day 1 pre-dose Day 5 ± 2 Day 14 ± 2 
TC 
Week 2 Month 1 Month 3 Month 6 
End-of-study 
visit 
IC x         
Demography and substance use x         
Physical examination x x  x     x 
Weight x x x x     x 
Height and BMI x         
Daytime oxygen saturation (SpO2) x         
HR and BP x x x x  x x x x 
12-lead ECG x x1 x x  x x x x 
Laboratory safety assessments  
Haematology x x  x  x x x x 
Chemistry x x2  x2  x2 x2 x2 x2 
Urinalysis x x  x  x x x x 
Serology x         
Testing ability to swallow capsules x         
Pregnancy test for females of childbearing 
potential x x     x  x 
24-hour Holter ECG x   x      
Eligibility criteria and decision of entry x         
Study treatment  x  
SVC x3 x4 x4 x4  x4 x4 x4  
TC = telephone contact; BMI = body mass index; CGI-C = Clinical Global Impression of Change; VAS = visual analogue scale; EQ-5D-5L = European Quality 
of Life Five Dimension Five Level Scale; SF-36 = Short-form health survey; PK = pharmacokinetics; PG = pharmacogenomics; SAE = 
1 3 baseline recordings 
2 Except thyroid-stimulating hormone (TSH) 
3 Only in sitting position 
4 In sitting and supine position 
5 No pre-dose sample during the 1st treatment period 
6 One sample preferably during visit 1 of the 1st treatment period 
SNP  x x x  x x x  
Overnight oxygen saturation (SpO2)  x x x  x x x  
Maximal grip strength and submaximal grip 
strength endurance  x x x      
CGI-C   x x      
VAS addressing fatigue  x x x      
EQ-5D-5L  x  x  x x x  
ALSFRS-R scoring  x  x  x x x  
SF-36  x  x  x x x  
Blood sampling for levosimendan PK  x5 x x      
Blood sampling for riluzole concentration  x  x      
Blood sample for exploratory biomarkers  x    x  x  
Blood sample for PG  x6      
Non-invasive ventilator support, permanent 
continuous ventilator dependence, tracheostomy 
and survival status 
 x 
Medical history and current medical conditions x 
AEs and SAEs x 
Concomitant treatments x 
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Online supplementary table 3. Plasma concentrations of levosimendan metabolites OR-1855 and 
OR-1896 (by acetylation status) prior to the study treatment intake in the morning of day 14 of a 
crossover study period.  
Acetylation status 
Levosimendan daily dose 1 mg 1 mg bd 
Analyte OR-1855 (ng/ml) 
OR-1896 
(ng/ml) 
OR-1855 
(ng/ml) 
OR-1896 
(ng/ml) 
Slow acetylators 
N 16 16 15 15 
Mean (SD) 1.82 (0.91) 1.10 (0.52) 3.72 (2.67) 2.24 (1.29) 
Slow (or intermediate) 
acetylators 
N 14 14 11 11 
Mean (SD) 1.69 (1.11) 1.21 (0.51) 4.59 (1.84) 2.60 (1.08) 
Intermediate (or rapid) 
acetylators 
N 23 23 23 23 
Mean (SD) 0.80 (0.47) 1.82 (0.94) 2.09 (1.16) 4.55 (1.97) 
Rapid acetylators 
N 3 3 3 3 
Mean (SD) 0.82 (0.26) 3.01 (0.32) 1.80 (0.66) 6.18 (0.47) 
Status unavailable 
N 2 2 3 3 
Mean (SD) 2.08 (1.70) 3.01 (1.05) 7.14 (4.82) 16.1 (4.20) 
All 
N 58 58 55 55 
Mean (SD) 1.34 (0.94) 1.58 (0.89) 3.30 (2.42) 4.25 (3.56) 
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Online Supplemental Figure 1. Study design. Double-blind part consisting of three 14-day cross-over 
treatment periods separated by 19-23 –day wash-out periods. Visits at day 1, 5 and 14 of each 
treatment period. Six-month open-label follow-up with visits at 1, 3 and 6 months. 
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Online supplementary figure 2. SVC (percent of predicted normal) measured in the supine position 
with original baseline definition. Change from baseline (period 1 day 1) in percent predicted SVC is 
shown for all three 14-day cross-over treatment periods separately. 
 
 
 
 
